Used in cancer immunotherapy to block the TIGIT receptor on immune cells, enhancing anti-tumor immune responses. It helps restore T cell and natural killer (NK) cell activity, which tumors often suppress. Commonly applied in research and clinical development for solid tumors and hematologic malignancies, often in combination with PD-1/PD-L1 inhibitors to improve therapeutic efficacy. Supports immune checkpoint inhibitor studies and is used as a reference standard in bioassays, potency testing, and antibody development.